glp-1 regulatory news The Ministry of Health and Family Welfare announced intensified surveillance on the supply and promotion of weight loss drugs to ensure ethical pharmaceutical practices. Acting through the Drugs Controller General Societies take stand against off-brand

Clin Case Rep

Despite some data showing differing bioavailability by injection site, the FDA highlights that the maximal subcutaneous bioavailability of semaglutide is 89%

PMID 28340339.

[box type=note]The study authors noted that the daily dose of 1.5 g/d of GPLC taken for 28 days resulted in similar improvements anaerobic sprint performance to taking a single dose of 4.5 g prior to exercise

Decisions should be individualized by weighing the mothers metabolic needs and available alternatives against the uncertainty about infant exposure

A perhaps surprising appearance in the top five focus areas was Prader-Willi syndrome, which is the focus of 56 studies